**Core Concept:**

The question is asking about the pharmacological management of coronary artery disease (CAD) and its association with type II diabetes mellitus, particularly in the context of obesity measured by a high Body Mass Index (BMI). CAD is a crucial topic for postgraduate medical students, as it relates to appropriate drug selection and patient risk stratification.

**Why the Correct Answer is Right:**

The correct answer, **D:** atorvastatin, belongs to a class of medications known as HMG-CoA reductase inhibitors or statins. These drugs are used in the management of dyslipidemia, a risk factor for CAD, by reducing low-density lipoprotein (LDL) cholesterol levels and increasing high-density lipoprotein (HDL) cholesterol levels. In this case, atorvastatin lowers LDL cholesterol, which is beneficial for the patient's risk of myocardial infarction (MI).

**Why Each Wrong Option is Incorrect:**

Option **A (simvastatin)** is also a statin, but it is not the most appropriate choice due to its lower potency compared to atorvastatin.

Option **B (rosuvastatin)** is another statin, but it is more potent than atorvastatin and thus is not the best choice for this patient, who has a high BMI and type II diabetes.

Option **C (simvastatin)** is another statin, but again, it is less potent than atorvastatin and may not effectively reduce the patient's risk of MI.

**Clinical Pearl:**

In patients with type II diabetes, obesity (as indicated by a high BMI), and coronary artery disease risk factors, such as the presence of proximal coronary arterial narrowing, statins like atorvastatin are essential for reducing the risk of myocardial infarction. Statins help lower LDL cholesterol levels and increase HDL cholesterol levels, thereby improving cardiovascular outcomes.

**Correct Answer:**

**D (atorvastatin)** is the appropriate choice due to its moderate potency among statins and its ability to lower LDL cholesterol effectively in a patient with high BMI and type II diabetes.